These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 37817156)
1. Insulin-degrading enzyme (IDE) as a modulator of microglial phenotypes in the context of Alzheimer's disease and brain aging. Corraliza-Gomez M; Bermejo T; Lilue J; Rodriguez-Iglesias N; Valero J; Cozar-Castellano I; Arranz E; Sanchez D; Ganfornina MD J Neuroinflammation; 2023 Oct; 20(1):233. PubMed ID: 37817156 [TBL] [Abstract][Full Text] [Related]
2. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421 [TBL] [Abstract][Full Text] [Related]
3. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Zhao L; Yao J; Mao Z; Chen S; Wang Y; Brinton RD Neurobiol Aging; 2011 Nov; 32(11):1949-63. PubMed ID: 20053478 [TBL] [Abstract][Full Text] [Related]
4. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Qiu WQ; Folstein MF Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206 [TBL] [Abstract][Full Text] [Related]
5. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348 [TBL] [Abstract][Full Text] [Related]
6. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Farris W; Mansourian S; Leissring MA; Eckman EA; Bertram L; Eckman CB; Tanzi RE; Selkoe DJ Am J Pathol; 2004 Apr; 164(4):1425-34. PubMed ID: 15039230 [TBL] [Abstract][Full Text] [Related]
8. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease. Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544 [TBL] [Abstract][Full Text] [Related]
9. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. Vekrellis K; Ye Z; Qiu WQ; Walsh D; Hartley D; Chesneau V; Rosner MR; Selkoe DJ J Neurosci; 2000 Mar; 20(5):1657-65. PubMed ID: 10684867 [TBL] [Abstract][Full Text] [Related]
11. New Insights on the Regulation of the Insulin-Degrading Enzyme: Role of microRNAs and RBPs. Martín-Martín Y; Pérez-García A; Torrecilla-Parra M; Fernández-de Frutos M; Pardo-Marqués V; Casarejos MJ; Busto R; Ramírez CM Cells; 2022 Aug; 11(16):. PubMed ID: 36010613 [TBL] [Abstract][Full Text] [Related]
12. Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. Kulas JA; Franklin WF; Smith NA; Manocha GD; Puig KL; Nagamoto-Combs K; Hendrix RD; Taglialatela G; Barger SW; Combs CK Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E106-E120. PubMed ID: 30422705 [TBL] [Abstract][Full Text] [Related]
14. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme. Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review. Azam MS; Wahiduzzaman M; Reyad-Ul-Ferdous M; Islam MN; Roy M Pharm Res; 2022 Apr; 39(4):611-629. PubMed ID: 35378698 [TBL] [Abstract][Full Text] [Related]
16. Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease. Kim DH; Lee D; Lim H; Choi SJ; Oh W; Yang YS; Chang JH; Jeon HB Biochem Biophys Res Commun; 2018 Oct; 504(4):933-940. PubMed ID: 30224067 [TBL] [Abstract][Full Text] [Related]
17. Somatostatin modulates insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD. Tundo G; Ciaccio C; Sbardella D; Boraso M; Viviani B; Coletta M; Marini S PLoS One; 2012; 7(4):e34376. PubMed ID: 22509294 [TBL] [Abstract][Full Text] [Related]
18. Evolutionary Origin of Insulin-Degrading Enzyme and Its Subcellular Localization and Secretion Mechanism: A Study in Microglial Cells. Corraliza-Gómez M; Lillo C; Cózar-Castellano I; Arranz E; Sanchez D; Ganfornina MD Cells; 2022 Jan; 11(2):. PubMed ID: 35053342 [TBL] [Abstract][Full Text] [Related]
19. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. Abdul-Hay SO; Kang D; McBride M; Li L; Zhao J; Leissring MA PLoS One; 2011; 6(6):e20818. PubMed ID: 21695259 [TBL] [Abstract][Full Text] [Related]
20. The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. de Tullio MB; Morelli L; Castaño EM Prion; 2008; 2(2):51-6. PubMed ID: 19098445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]